Enterprise Value

100.4M

Cash

28.8M

Avg Qtr Burn

-6.059M

Short % of Float

0.28%

Insider Ownership

7.10%

Institutional Own.

21.23%

Qtr Updated

09/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Approved

Quarterly sales

belzupacap saratalocan (bel-sar) (AU-011) Details
Primary Choroidal Melanoma, Cancer

Phase 3

Update

CLS-AX Details
Wet age-related macular degeneration , Age-related macular degeneration

Phase 2b

Data readout

RGX-314 Details
Wet age-related macular degeneration , Age-related macular degeneration

Phase 2

Update

ABBV-RGX-314 Details
Diabetic retinopathy

Phase 2

Update